Released Nov 15, 2021, after the close
10-Q filed Nov 15, 2021, 46 days after period end · 0001493152-21-028584
Q2 2022 · 10-Q
Revenue$8.56M$8.56M +15.7% vs Q2 2021+21.3% vs Q1 2022
Net Income$1.80M$1.80M −27.6% vs Q2 2021−24.8% vs Q1 2022
EPS Diluted$0.00$0.00 — vs Q2 2021no prior Q1 2022 on file
Gross Profit$3,768,149+4.1%
Operating Income$1,422,577+6.1%
Operating Cash Flowderived$153,785−91.9%
Margins · derived
Gross margin44.0%−4.9 pt vs Q2 2021
Operating margin16.6%−1.5 pt vs Q2 2021
Net margin21.0%−12.5 pt vs Q2 2021
What the release said
The release
Same quarter
| Metric | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 |
|---|---|---|---|---|
| Revenue | $8.56M | $7.40M | $4.63M | $1.36M |
| Net Income | $1.80M | $2.48M | -$1.60M | -$2.58M |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Elite Pharmaceuticals Inc · CIK 1053369 · Engraved from SEC EDGAR